Exclusive interview with Aptorum Group (NASDAQ: APM) President Darren Lui

Facebooktwitterlinkedinmail

Aptorum is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum’s current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases, and the company intends to bring two candidates to clinical phases in 2020. Aptorum’s Smart-ACT™ platform targets to bring an average of three drug candidates for orphan diseases to clinical phases every 12-18 months. Near-term launch of a dietary supplement for women undergoing menopause and experiencing related symptoms including osteoporosis, targeting a global woman’s health supplement market that is expected to reach $17 billion in 2025, is expected to generate revenue in the next 12 months.

Facebooktwitterlinkedinmail